A Multicenter, Non-interventional, Descriptive Study to Assess Assay Concordance of HER2 IHC Testing in Chinese Pan-tumor Patients
← catalyst calendarNCT07404202 · readout in 134 d
Sponsored by AstraZeneca (industry) · AZN — their whole pipeline →.
Phase
—
Status
Recruiting
Study type
Observational
Enrollment
2,100estimated
Sites
14
Country
China
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2026-03-06 | actual | When the study began enrolling |
| Primary completion | 2026-12-31 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2026-12-31 | estimated | The whole study's end, after follow-up |
| First posted | 2026-02-11 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-08-11 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Pan-tumor(NSCLC, GYN Cancers, BTC and UC)
Primary outcomes
what the primary-completion date above is the date OFNPA of HER2 IHC 3+ based on confusion matrix results betwee other assays(Roche 4B5\MXB\Zhongshan\An Biping\Amoy) and HercepTest
measured From the assessment phase start to the final slides interpreted，up to approximately 6 month
PPA of HER2 IHC 3+ based on confusion matrix results between other assays(Roche 4B5\MXB\Zhongshan\An Biping\Amoy) and HercepTest
measured From the assessment phase start to the final slides interpreted，up to approximately 6 month
Permalink · AZN's whole pipeline · Catalyst calendar · Every registered study · What changed